An interventional study of Invasive coronary angiography and Non-invasive functional test in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 22 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 21st registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 520 across the 21 interventional studies, 16,487 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
3 of the studies in Coronary Artery Disease by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT04014803Samsung Medical CenterAspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion | 2027-06-30 |
| NCT05221931Samsung Medical CenterDrug-Coated Balloon in Patients With High Bleeding Risk | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pragmatic, prospective, multi-center, open label, randomized controlled, superiority trial.
The study will compare clinical outcomes between invasive versus non-invasive approach as next diagnostic step in symptomatic patients with non-high risk obstructive coronary artery disease (CAD) on coronary computed tomography-angiography (CCTA).
CCTA has been emerged as useful diagnostic tool to evaluate CAD. Besides high diagnostic accuracy, CCTA has additional benefit of measuring the cumulative atherosclerotic burden and more accurately discriminating obstructive CAD with additional fractional flow reserve by CT (FFRCT), making it more predictive of a patient's prognosis. Recently, several randomized clinical trials have demonstrated the clinical utility of CCTA when compared with noninvasive stress test, which has been previously widely used as an initial assessment for stable chest pain, or invasive coronary angiography, which is the gold standard for diagnosing obstructive CAD.
On this background, CCTA, along with stress imaging test, is recommended as first step to diagnose obstructive CAD in patients with intermediate to high pretest probabilities with stable chest pain and is increasingly utilized. Although CCTA is increasingly used as initial assessment tool in these patients, there are insufficient studies to clearly establish the next step after obstructive CAD is confirmed in CCTA. Without high-risk features of CAD on CCTA, current guidelines suggest noninvasive stress imaging or FFRCT as class IIA recommendation. However, supporting evidence of these suggestions are mostly based on studies with low level of evidence. Furthermore, given the limited diagnostic performance of noninvasive stress test, concern remains whether it is safe to defer invasive coronary angiography based on the result from noninvasive stress test in patients with obstructive CAD on CCTA.
Therefore, this trial aims to compare clinical outcomes between invasive versus non-invasive approach as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Invasive coronary angiography will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA..
Diagnostic Test: Invasive coronary angiography
Usual care of non-invasive ischemia testing (exercise electrocardiography \[ECG\], stress echocardiography by exercise or pharmacologic agent, nuclear test including SPECT or PET, stress cardiac magnetic resonance \[MR\]) will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.
Diagnostic Test: Non-invasive functional test
As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
Standard non-invasive functional testing will be performed.
Time to first event of major adverse cardiac events (MACE)
MACE is a composite of death from any causes, myocardial infarction (MI), clinically driven unplanned revascularization.
Time frame: 2 years after the last patient enrollment
All-cause death
All-cause death
Time frame: 2 years after the last patient enrollment
Cardiac death
Cardiac death
Time frame: 2 years after the last patient enrollment
Any MI
Defined by Forth Universal definition of MI
Time frame: 2 years after the last patient enrollment
Spontaneous MI
Defined by Forth Universal definition of MI
Time frame: 2 years after the last patient enrollment
Procedure-related MI
Defined by ARC II definition
Time frame: 2 years after the last patient enrollment
Resuscitated cardiac arrest
Resuscitated cardiac arrest
Time frame: 2 years after the last patient enrollment
Unplanned revascularization (clinically driven)
Unplanned revascularization (clinically driven)
Time frame: 2 years after the last patient enrollment
Cerebrovascular accidents
Cerebrovascular accidents (ischemic or hemorrhagic)
Time frame: 2 years after the last patient enrollment
Major adverse cardiac and cerebrovascular events
Major adverse cardiac and cerebrovascular events (MACCE, a composite of death, MI, clinically-driven unplanned revascularization, or cerebrovascular accident)
Time frame: 2 years after the last patient enrollment
Rate of index coronary angiography
Rate of index coronary angiography
Time frame: up to 30 days following randomization
Rate of index revascularization by PCI or CABG
Rate of index revascularization by PCI or CABG
Time frame: up to 30 days following randomization
European Quality of Life-5 Dimensions
European Quality of Life-5 Dimensions
Time frame: 6 months after initial management according to allocated diagnostic test
Seattle Angina Questionnaire
Seattle Angina Questionnaire
Time frame: 6 months after initial management according to allocated diagnostic test
Total medical cost
Total medical cost
Time frame: 2 years after the last patient enrollment
Procedure-related complications from invasive procedure
Procedure-related complications from invasive procedure
Time frame: up to 30 days following randomization
Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Access criteria: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Jun 2029, 68 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 68 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.